Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
Equillium, Inc. submitted a Form 144 notice related to proposed sales of common stock by an affiliate. The filing lists 30,975 shares in the "Securities To Be Sold" section and records a 200,000-share sale by Stephen Connelly on 06/04/2026 reported under "Securities Sold During The Past 3 Months." The broker listed is Jefferies LLC.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sale transaction in company stock. She exercised employee stock options to acquire 14,584 shares of common stock at an exercise price of $0.7850 per share, then sold 14,584 shares in an open-market transaction at a weighted average price of $2.9304 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2025, indicating it was scheduled in advance. After these transactions, she holds 62,586 shares of common stock directly and 25,521 stock options that remain outstanding and unexercised.
Equillium, Inc. President and CSO Stephen Connelly reported open-market sales of company common stock. He sold 200,000 shares on June 4, 2026 at a weighted average price of $3.1638 per share, in multiple trades between $3.07 and $3.345.
On June 5, 2026, he sold an additional 30,975 shares at a weighted average price of $2.9401, in trades between $2.83 and $3.06. After these transactions, he directly holds 762,025 shares of Equillium common stock.
Equillium, Inc. Principal Accounting Officer Tom Penny exercised options and sold shares in a coordinated transaction. He exercised an employee stock option to acquire 65,000 shares of Common Stock at $0.785 per share, then sold 65,000 shares in an open-market transaction at a weighted average price of $2.95 per share, with individual sale prices ranging from $2.95 to $2.99. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2025, indicating they were scheduled in advance. Following these transactions, Penny reported owning no shares of Common Stock and the corresponding option for 65,000 shares was fully exercised with no remaining balance.
Equillium, Inc. director Martha J. Demski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and were awarded as compensation, not purchased in the open market.
The option vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested by the company’s next annual meeting of stockholders following the grant date. Following this grant, Demski holds derivative rights over 70,000 shares through this option award.
Equillium, Inc. director Mark Pruzanski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.8400 per share and bring his directly held option position reported in this filing to 70,000 derivative securities.
According to the terms, the option vests in twelve equal monthly installments starting on the grant date of May 28, 2026, and will in any case be fully vested on the date of Equillium's annual meeting of stockholders following that grant date. The option expires on May 27, 2036.
Equillium, Inc. disclosed that chairman and director Daniel Bradbury received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments beginning on May 28, 2026, and will in any case be fully vested on the date of Equillium’s next annual meeting of stockholders following the grant date. This is a compensation-related equity grant, not an open-market share purchase or sale.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported a set of option exercises paired with open-market sales of common stock. She exercised employee stock options to acquire 95,833 shares at strike prices between $0.73 and $0.785 per share, then sold 95,833 shares at market prices around the high $2 range. After these transactions, she directly holds 62,586 shares of Equillium common stock. A footnote states that at least part of the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.
Equillium, Inc. director Charles Douglas McDermott received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested on the date of Equillium's next annual meeting of stockholders following the grant date. Following this grant, McDermott holds 70,000 derivative securities directly.